By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- Current study results on Biotechnology have been published. According to news reporting originating in Shenyang, People's Republic of China, by NewsRx journalists, research stated, "Osteosarcoma is an aggressive cancerous neoplasm arising from primitive transformed cells of mesenchymal origin that exhibit osteoblastic differentiation and produce malignant osteoid. With the rapid development of tumor molecular biology, gene and viral therapy, a highly promising strategy for the treatment, has shown some therapeutic effects."
The news reporters obtained a quote from the research from China Medical University and Hospital, "To study the strategy of cooperative cancer gene therapy, previously, we explored the antitumor effects of recombinant Fowl-pox viruses (FPVs) with both HN (hemagglutinin-neuramidinase) and VP3 genes on mouse osteosarcoma. We constructed vFV-HN, vFV-VP3 and vFV-HN-VP3 inserting CAV VP3 gene, NDV HN gene into fowlpox virus. S180 osteosarcoma were transfected with Recombinant Fowl-pox viruses (FPVs). These cell lines stably expressing tagged proteins were selected by culturing in medium containing puromycin (2 mu g/ml) and confirmed by immunoblotting and immunostaining. S180 osteosarcoma model with BALB/c mice and nude mice were established and the vFPV viruses as control, vFV-HN, vFV-VP3, vFV-HN-VP3 were injected into the tumor directly. The rate of tumor growth, tumor suppression and the sialic acid levels in serum were examined and the tumor tissues were analyzed by the method of immunohistochemistry. Flow cytometric analysis was performed using a FAC-SCalibur flow cytometer. A total of 100,000 events were analyzed for each sample and the experiment was repeated at least twice. Our data indicated that vFV-HN, vFV-VP3 and vFV-HN-VP3 all had growth inhibition effects, the inhibition rate of vFV-HN-VP3 group was 51.7%, which was higher than that of vFV-HN, vFV-VP3 group and control group (p < 0.01). The sialic acid level of vFV-HN-VP3 group in mouse serum was 4.22 +/- 0.27 mmol/l, which was lower than that of other groups (p < 0.01)."
According to the news reporters, the research concluded: "These results suggest that genes into mouse osteosarcoma cancer cells can cause cell a specificity anti-tumor immune activity, suppress tumor growth, and increase the survival rate of the tumor within host."
For more information on this research see: Combination of targeting gene-viro therapy with recombinant Fowl-pox viruses with HN and VP3 genes on mouse osteosarcoma. European Review for Medical and Pharmacological Sciences, 2013;17(6):767-776. European Review for Medical and Pharmacological Sciences can be contacted at: Verduci Publisher, Via Gregorio Vii, Rome, 186-00165, Italy (see also technology.html">Biotechnology).
Our news correspondents report that additional information may be obtained by contacting Z.Y. Zhang, 95K China Med Univ, Shenyang, People's Republic of China. Additional authors for this research include L.Q. Wang, C.F. Fu, X. Li, Z.L. Cui, J.Y. Zhang, S.H. Xue, N. Sun and F. Xu.
Keywords for this news article include: Asia, Biotechnology, Viruses, Shenyang, Virology, Bioengineering, Cancer Gene Therapy, People's Republic of China, Clinical Trials and Studies
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC